New drug aims to reach brain tumors in recurrent glioblastoma
NCT ID NCT06883747
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a drug called BMS-986504 in up to 12 people with recurrent glioblastoma, a severe brain cancer. The drug targets tumors with a specific genetic change (MTAP loss). The study first checks if the drug can reach the brain tumor during surgery, then looks at safety and side effects. If the drug gets into the tumor well, participants may continue treatment to see if it helps control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BMS-986504 (MRTX1719), a targeted drug that blocks a protein called PRMT5, which helps certain cancer cells grow
- What this could lead to
- If it works, this could point toward a new treatment option for people with recurrent glioblastoma whose tumors have a specific genetic change (MTAP loss).
- What could go wrong
- This is a very early (Phase 0/1) and small trial (12 people). It mainly checks if the drug reaches the brain and is safe, not if it shrinks tumors. Many early drugs fail to show benefit in later studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA WHO GRADE IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
St. Joseph's Hospital and Medical Center
RECRUITINGPhoenix, Arizona, 85013, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.